http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03032988-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0101a0aa0078676a1e24511c2abab8ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f6e33603375c486b0ab3505830af9e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_586c8e5275d0ac397d29028f3c4a7939
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b424fd8882fe96d1742e40c6c322b93
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2002-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63ca268aaa6c142e4d6f73864127dee8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56a7f1fb7aa689a22c92c3760369f785
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d0911ad063bd2c9d53acd03ebf3bc04
publicationDate 2003-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-03032988-A1
titleOfInvention Pharmaceutical composition
abstract A pharmaceutical composition for administering a compound represented by the general formula (I) or the like and a compound represented by the general formula (II) either simultaneously or separately at a time interval: (I) (II) wherein X is a benzimidazole ring group; Y1 is oxygen or sulfur; Z is a thiazolidinedione group or the like; R is hydrogen, C1-6 alkyl, or the like; m is an integer of 1 to 5; Ra is bromo or iodo; Rb is hydrogen, halogeno, or the like; Rc is -NRkORl [wherein Rk is hydrogen or the like; and Rl is C3-10 cycloalkyl or the like]; and Rd, Re and Rf are each independently hydrogen, halogeno, or the like.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2007213028-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2007213028-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010070379-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8263631-B2
priorityDate 2001-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0061581-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000351779-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9837881-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1022272-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9825598-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID542717
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397561
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397562
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5798
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128635168

Total number of triples: 42.